239 related articles for article (PubMed ID: 37198696)
1. CircZNF215 promotes tumor growth and metastasis through inactivation of the PTEN/AKT pathway in intrahepatic cholangiocarcinoma.
Liao W; Du J; Li L; Wu X; Chen X; Feng Q; Xu L; Chen X; Liao M; Huang J; Yuan K; Zeng Y
J Exp Clin Cancer Res; 2023 May; 42(1):125. PubMed ID: 37198696
[TBL] [Abstract][Full Text] [Related]
2. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways.
Tiemin P; Fanzheng M; Peng X; Jihua H; Ruipeng S; Yaliang L; Yan W; Junlin X; Qingfu L; Zhefeng H; Jian L; Zihao G; Guoxing L; Boshi S; Ming Z; Qinghui M; Desen L; Lianxin L
J Hepatol; 2020 Apr; 72(4):761-773. PubMed ID: 31837357
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of celastrol by inhibition of proliferation, invasion, and migration in cholangiocarcinoma via PTEN/PI3K/Akt pathway.
Zhu B; Wei Y
Cancer Med; 2020 Jan; 9(2):783-796. PubMed ID: 31957323
[TBL] [Abstract][Full Text] [Related]
4. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
[TBL] [Abstract][Full Text] [Related]
5. FUT8 is regulated by miR-122-5p and promotes malignancies in intrahepatic cholangiocarcinoma via PI3K/AKT signaling.
Chen F; Li Y; Aye L; Wu Y; Dong L; Yang Z; Gao Q; Zhang S
Cell Oncol (Dordr); 2023 Feb; 46(1):79-91. PubMed ID: 36348252
[TBL] [Abstract][Full Text] [Related]
6. CircNFIB inhibits tumor growth and metastasis through suppressing MEK1/ERK signaling in intrahepatic cholangiocarcinoma.
Du J; Lan T; Liao H; Feng X; Chen X; Liao W; Hou G; Xu L; Feng Q; Xie K; Liao M; Chen X; Huang J; Yuan K; Zeng Y
Mol Cancer; 2022 Jan; 21(1):18. PubMed ID: 35039066
[TBL] [Abstract][Full Text] [Related]
7. Tetraspanin 1 promotes epithelial-to-mesenchymal transition and metastasis of cholangiocarcinoma via PI3K/AKT signaling.
Wang Y; Liang Y; Yang G; Lan Y; Han J; Wang J; Yin D; Song R; Zheng T; Zhang S; Pan S; Liu X; Zhu M; Liu Y; Cui Y; Meng F; Zhang B; Liang S; Guo H; Liu Y; Hassan MK; Liu L
J Exp Clin Cancer Res; 2018 Dec; 37(1):300. PubMed ID: 30514341
[TBL] [Abstract][Full Text] [Related]
8. Circ_0004018 suppresses cell proliferation and migration in hepatocellular carcinoma via miR-1197/PTEN/PI3K/AKT signaling pathway.
Wang H; Zhang Q; Cui W; Li W; Zhang J
Cell Cycle; 2021 Oct; 20(20):2125-2136. PubMed ID: 34570663
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
Lu C; Shan Z; Hong J; Yang L
Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
[TBL] [Abstract][Full Text] [Related]
10. Tip60 Suppresses Cholangiocarcinoma Proliferation and Metastasis via PI3k-AKT.
Zhang Y; Ji G; Han S; Shao Z; Lu Z; Huo L; Zhang J; Yang R; Feng Q; Shen H; Wang H; Li X
Cell Physiol Biochem; 2018; 50(2):612-628. PubMed ID: 30308494
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial transplantation inhibits cholangiocarcinoma cells growth by balancing oxidative stress tolerance through PTEN/PI3K/AKT signaling pathway.
Liu X; Zhang Y; Yang X; Zhang Y; Liu Y; Wang L; Yi T; Yuan J; Wen W; Jian Y
Tissue Cell; 2023 Dec; 85():102243. PubMed ID: 37865041
[TBL] [Abstract][Full Text] [Related]
12. CircHERC1 promotes non-small cell lung cancer cell progression by sequestering FOXO1 in the cytoplasm and regulating the miR-142-3p-HMGB1 axis.
Cui Y; Wu X; Jin J; Man W; Li J; Li X; Li Y; Yao H; Zhong R; Chen S; Wu J; Zhu T; Lin Y; Xu J; Wang Y
Mol Cancer; 2023 Nov; 22(1):179. PubMed ID: 37932766
[TBL] [Abstract][Full Text] [Related]
13. Microsomal prostaglandin E synthase-1 inhibits PTEN and promotes experimental cholangiocarcinogenesis and tumor progression.
Lu D; Han C; Wu T
Gastroenterology; 2011 Jun; 140(7):2084-94. PubMed ID: 21354147
[TBL] [Abstract][Full Text] [Related]
14. CircPCNXL2 promotes tumor growth and metastasis by interacting with STRAP to regulate ERK signaling in intrahepatic cholangiocarcinoma.
Liu S; Wang Y; Wang T; Shi K; Fan S; Li C; Chen R; Wang J; Jiang W; Zhang Y; Chen Y; Xu X; Yu Y; Li C; Li X
Mol Cancer; 2024 Feb; 23(1):35. PubMed ID: 38365721
[TBL] [Abstract][Full Text] [Related]
15. JUND/linc00976 promotes cholangiocarcinoma progression and metastasis, inhibits ferroptosis by regulating the miR-3202/GPX4 axis.
Lei S; Cao W; Zeng Z; Zhang Z; Jin B; Tian Q; Wu Y; Zhang T; Li D; Hu C; Lan J; Zhang J; Chen T
Cell Death Dis; 2022 Nov; 13(11):967. PubMed ID: 36400758
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
17. Circular RNA hsa_circ_0000317 inhibits non-small cell lung cancer progression through regulating microRNA-494-3p/phosphatase and tensin homolog deleted on chromosome 10 axis.
Xia S; Zhang Z
Clinics (Sao Paulo); 2022; 77():100086. PubMed ID: 35917658
[TBL] [Abstract][Full Text] [Related]
18. LncRNA GAS5 Suppresses the Proliferation and Invasion of Osteosarcoma Cells via the miR-23a-3p/PTEN/PI3K/AKT Pathway.
Liu J; Chen M; Ma L; Dang X; Du G
Cell Transplant; 2020; 29():963689720953093. PubMed ID: 33121268
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma.
Chen MH; Chiang KC; Cheng CT; Huang SC; Chen YY; Chen TW; Yeh TS; Jan YY; Wang HM; Weng JJ; Chang PM; Liu CY; Li CP; Chao Y; Chen MH; Huang CY; Yeh CN
Oncotarget; 2014 May; 5(9):2372-89. PubMed ID: 24796583
[TBL] [Abstract][Full Text] [Related]
20. The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease.
Cigliano A; Zhang S; Ribback S; Steinmann S; Sini M; Ament CE; Utpatel K; Song X; Wang J; Pilo MG; Berger F; Wang H; Tao J; Li X; Pes GM; Mancarella S; Giannelli G; Dombrowski F; Evert M; Calvisi DF; Chen X; Evert K
J Exp Clin Cancer Res; 2022 Jun; 41(1):192. PubMed ID: 35655220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
